Striverdi Respimat: Uses, Dosage & Side Effects

What Is Striverdi Respimat and What Is It Used For?

Striverdi Respimat contains the active substance olodaterol, a potent and highly selective long-acting beta-2 adrenergic receptor agonist (LABA). Beta-2 adrenergic receptors are found in high density on the smooth muscle cells lining the bronchi and bronchioles of the lungs. When olodaterol binds to these receptors, it activates an intracellular signaling cascade that ultimately leads to relaxation of the airway smooth muscle. Specifically, receptor activation stimulates the enzyme adenylyl cyclase, which increases intracellular levels of cyclic adenosine monophosphate (cAMP). Elevated cAMP activates protein kinase A, which phosphorylates multiple target proteins, reducing intracellular calcium levels and inhibiting myosin light chain kinase activity. The net effect is smooth muscle relaxation and bronchodilation.

Olodaterol demonstrates a rapid onset of action, with bronchodilation beginning within approximately 5 minutes after inhalation. Its prolonged duration of action – maintaining clinically meaningful bronchodilation for a full 24 hours – distinguishes it as a true once-daily LABA. This pharmacodynamic profile is attributed to olodaterol's high binding affinity for the beta-2 receptor and its slow dissociation kinetics, which allows it to remain associated with the receptor for extended periods. The selectivity of olodaterol for beta-2 receptors over beta-1 receptors (found primarily in the heart) is approximately 241-fold in vitro, contributing to its favorable cardiovascular safety profile at therapeutic doses.

Chronic obstructive pulmonary disease (COPD) is a progressive and largely irreversible lung condition characterized by persistent airflow limitation. It encompasses two main pathological processes: chronic bronchitis (inflammation and mucus hypersecretion in the airways) and emphysema (destruction of the lung's gas-exchanging surfaces, the alveoli). According to the World Health Organization (WHO), COPD is the third leading cause of death globally, affecting an estimated 380 million people worldwide. The disease is most commonly caused by long-term exposure to cigarette smoke, although occupational dust and chemical exposure, biomass fuel smoke, and genetic factors (such as alpha-1 antitrypsin deficiency) also contribute significantly.

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 report recommends long-acting bronchodilators as the cornerstone of pharmacological maintenance therapy for COPD. LABAs such as olodaterol play a central role in symptom management by improving lung function, reducing breathlessness, enhancing exercise tolerance, and decreasing the frequency of exacerbations when used as part of a comprehensive treatment strategy. Striverdi Respimat is specifically indicated for maintenance bronchodilator treatment to reduce symptoms in patients with COPD and is taken every day, not just when breathing problems or other COPD symptoms occur.

Striverdi Respimat was evaluated in a comprehensive clinical development program. The pivotal phase III clinical trials (ANHELTO 1 and ANHELTO 2) were randomized, double-blind, placebo-controlled studies that enrolled over 1,800 patients with moderate-to-severe COPD. These studies demonstrated that olodaterol 5 mcg (two puffs of 2.5 mcg) once daily significantly improved trough FEV1 (forced expiratory volume in one second) compared with placebo over 48 weeks. Trough FEV1 is measured 24 hours after the last dose, providing a stringent measure of sustained bronchodilation. Additional studies (OTEMTO 1 and 2) evaluated olodaterol in combination with the long-acting muscarinic antagonist (LAMA) tiotropium, demonstrating that the fixed-dose combination (marketed as Spiolto Respimat) provided superior bronchodilation compared with either component alone.

What Should You Know Before Taking Striverdi Respimat?

Contraindications

Striverdi Respimat is contraindicated in patients with a known hypersensitivity (allergy) to olodaterol or to any of the excipients in the formulation. Allergic reactions may manifest as skin rash, itching, swelling, or difficulty breathing. If you have previously experienced an allergic reaction to olodaterol or any component of Striverdi Respimat, you must not use this medication.

Warnings and Precautions

Before starting Striverdi Respimat, it is essential that you discuss your complete medical history with your healthcare provider. Certain pre-existing conditions may require special monitoring or dosage adjustments during treatment. Inform your doctor if you have any of the following conditions:

• Heart disease: Beta-2 agonists can cause increases in heart rate and blood pressure, and may provoke cardiac arrhythmias. Patients with coronary artery disease, heart failure, or irregular heart rhythms should be monitored closely.
• High blood pressure (hypertension): Olodaterol may cause mild increases in blood pressure. Patients with uncontrolled hypertension should be treated with caution.
• Seizure disorders (epilepsy): Beta-2 agonists may lower the seizure threshold. Patients with epilepsy should discuss the risks and benefits of treatment with their physician.
• Thyroid disorders (thyrotoxicosis): Overactive thyroid function can amplify the cardiovascular effects of beta-2 agonists, including tachycardia and tremor.
• Aneurysm: Patients with known arterial aneurysms should use Striverdi Respimat with caution due to the potential for hemodynamic effects.
• Diabetes mellitus: Beta-2 agonists can cause transient increases in blood glucose levels by stimulating hepatic glycogenolysis and gluconeogenesis. Blood glucose monitoring may need to be intensified.
• Severe hepatic impairment: Striverdi Respimat has not been studied in patients with severe liver dysfunction. Use in this population should be considered only when the expected benefit outweighs potential risks.
• Severe renal impairment: Limited clinical experience exists in patients with severe kidney dysfunction. Close monitoring is recommended.
• Planned surgery: Inform your anesthesiologist that you are using a LABA, as beta-agonists can interact with certain anesthetic agents.

Striverdi Respimat is intended for maintenance therapy only. It must not be used to treat sudden attacks of breathlessness or wheezing (acute bronchospasm). If you experience a sudden worsening of COPD symptoms, use your prescribed short-acting rescue inhaler (such as salbutamol/albuterol) and seek medical attention if symptoms do not improve.

Stop using Striverdi Respimat and contact your doctor immediately if you experience chest tightness, coughing, wheezing, or shortness of breath immediately after using the inhaler. This may be a sign of paradoxical bronchospasm, a rare but potentially serious reaction in which the airways constrict rather than dilate following inhalation. If your breathing worsens or you develop skin rash, swelling, or itching immediately after inhalation, discontinue use and seek medical attention promptly.

Pregnancy and Breastfeeding

The safety of olodaterol during pregnancy has not been established in adequate human studies. Animal studies have shown reproductive toxicity at doses significantly higher than the therapeutic human dose, but the relevance of these findings to humans is uncertain. As a precaution, Striverdi Respimat should not be used during pregnancy unless the expected benefit to the mother justifies the potential risk to the fetus. If you are pregnant, suspect you may be pregnant, or are planning to become pregnant, consult your physician before using this medication.

It is not known whether olodaterol or its metabolites are excreted in human breast milk. In animal studies, olodaterol and its metabolites were found in the milk of lactating rats. A decision must be made whether to discontinue breastfeeding or to discontinue Striverdi Respimat therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. Discuss this with your doctor.

Children and Adolescents

Striverdi Respimat is not indicated for use in children or adolescents under 18 years of age. COPD is a condition that primarily affects adults, and there are no clinical data supporting the use of olodaterol in pediatric populations.

Driving and Operating Machinery

No formal studies have been conducted on the effect of Striverdi Respimat on the ability to drive or operate machinery. However, dizziness has been reported as an uncommon side effect. If you experience dizziness while using Striverdi Respimat, avoid driving or operating machinery until the symptom resolves.

How Does Striverdi Respimat Interact with Other Drugs?

Drug interactions can alter the effectiveness or safety of medications. It is critical that you inform your physician and pharmacist about all medications you are currently taking, including prescription drugs, over-the-counter medications, herbal supplements, and vitamins. The following interactions are particularly important to be aware of when using Striverdi Respimat:

Major Interactions

Minor Interactions

It is important to understand that olodaterol undergoes metabolic transformation primarily via direct glucuronidation and by O-demethylation at the methoxy group, followed by conjugation. The O-demethylation is catalyzed by the cytochrome P450 enzymes CYP2C9 and CYP2C8, with minor contributions from CYP3A4. However, given the low systemic exposure after inhalation and the multiple metabolic pathways involved, clinically relevant pharmacokinetic drug interactions are considered unlikely. No formal drug interaction studies have identified significant changes in olodaterol pharmacokinetics when co-administered with known CYP inhibitors.

What Is the Correct Dosage of Striverdi Respimat?

Adults

Striverdi Respimat is effective for 24 hours and therefore needs to be taken only once a day, ideally at the same time each day to maintain consistent bronchodilation. Each cartridge delivers 60 puffs (30 doses), providing one month of treatment when used as recommended. Because COPD is a chronic, progressive disease, Striverdi Respimat should be used every day as maintenance therapy, not only when breathing problems or other symptoms occur.

The medication is delivered via the Respimat soft mist inhaler, which generates a slow-moving aerosol mist that does not require coordination between actuation and inhalation to the same degree as traditional pressurized metered-dose inhalers. However, correct inhaler technique is essential for optimal drug delivery to the lungs. Your healthcare provider or pharmacist should demonstrate the proper technique before you use the inhaler for the first time.

Children

Striverdi Respimat is not indicated for use in children or adolescents under 18 years of age. There are no clinical data supporting the use of olodaterol in pediatric populations, and COPD is a disease that primarily affects adults with a long history of exposure to risk factors such as tobacco smoke.

Elderly

No dosage adjustment is required for elderly patients. The Respimat soft mist inhaler is particularly well-suited for older adults because the slow-moving aerosol mist does not require the strong inspiratory force needed by some dry powder inhalers. Clinical trials enrolled patients up to the age of 80 and beyond, and the efficacy and safety profile of olodaterol was consistent across age groups.

Missed Dose

If you forget to take a dose of Striverdi Respimat, take your next dose at the usual time the following day. Do not take a double dose to make up for a missed dose. Skipping a single dose is unlikely to cause significant worsening of your COPD, but consistent daily use is important for optimal symptom control.

Overdose

If you take more than the recommended dose of Striverdi Respimat, or if a child accidentally uses the medication, contact your local poison control center or seek emergency medical attention immediately. Symptoms of overdose may include chest pain, elevated or reduced blood pressure, rapid or irregular heartbeat, palpitations, dizziness, nervousness, difficulty sleeping, anxiety, headache, tremor, dry mouth, muscle cramps, nausea, fatigue, malaise, low potassium levels (which may cause muscle twitching, muscle weakness, or abnormal heart rhythm), high blood sugar, or metabolic acidosis (which may cause nausea, vomiting, weakness, muscle cramps, and rapid breathing).

Treatment of overdose is supportive and symptomatic. In severe cases, cardioselective beta-blockers may be considered, but should be used with extreme caution in COPD patients due to the risk of triggering bronchospasm.

What Are the Side Effects of Striverdi Respimat?

Like all medicines, Striverdi Respimat can cause side effects, although not everybody gets them. The side effects listed below have been reported by people using the medication and are categorized by their frequency of occurrence. It is important to understand that most patients tolerate olodaterol well, and the majority of reported adverse effects are mild and self-limiting.

If you experience side effects affecting your heart (increased heart rate, elevated blood pressure, chest pain), contact your physician promptly. While cardiovascular effects are well-recognized as a class effect of beta-2 agonists, they are uncommon with inhaled olodaterol at recommended doses due to the low systemic exposure achieved with inhalation delivery.

If you notice muscle twitching, muscle weakness, or abnormal heart rhythm, consult your doctor, as these symptoms may be related to low potassium levels in the blood (hypokalemia). This risk is increased when olodaterol is used concurrently with other medications that lower potassium, such as corticosteroids, diuretics, or theophylline.

How Should You Store Striverdi Respimat?

Proper storage of Striverdi Respimat is important to ensure that the medication remains effective and safe throughout its shelf life. Follow these storage guidelines:

• Temperature: Store at room temperature. Do not freeze the medication or the inhaler device.
• Light and humidity: Keep the inhaler in its original packaging to protect it from excessive light and moisture when not in use.
• Cartridge replacement: Replace the cartridge no later than 3 months after inserting it into the inhaler, even if the cartridge is not empty.
• Inhaler lifespan: Do not use the same Respimat reusable inhaler for longer than 1 year after the first cartridge is inserted. The recommended maximum use is up to 6 cartridges per inhaler, although the device has been tested and shown to function reliably with up to 9 cartridges (540 puffs).
• Expiry date: Do not use the medication after the expiry date printed on the carton and cartridge label (EXP). The expiry date refers to the last day of the stated month.
• Keep out of reach: Store out of the sight and reach of children at all times.
• Disposal: Do not throw unused medication in household waste or down the drain. Ask your pharmacist about proper disposal of medicines that are no longer needed. These measures help protect the environment.

If Striverdi Respimat has not been used for more than 7 days, point the inhaler downward and away from yourself, then release one puff before your next scheduled dose. If the inhaler has not been used for more than 21 days, you should repeat the initial priming procedure: twist, open, and press until a visible mist appears, then repeat three more times. This ensures that the first therapeutic dose is delivered correctly.

What Does Striverdi Respimat Contain?

Understanding the full composition of your medication is important, particularly if you have known allergies or sensitivities to specific ingredients. Striverdi Respimat contains the following:

Active Ingredient

Olodaterol (as hydrochloride): Each actuation (puff) delivers 2.5 micrograms of olodaterol. The delivered dose is the amount available to the patient after passage through the mouthpiece. The standard daily dose is two puffs, providing a total of 5 micrograms of olodaterol per day.

Inactive Ingredients (Excipients)

• Benzalkonium chloride: A preservative (0.0011 mg per puff). May cause wheezing and breathing difficulties in sensitive individuals, particularly those with asthma.
• Disodium edetate (EDTA): A stabilizing agent that helps maintain the chemical stability of the solution.
• Purified water: The solvent for the inhalation solution.
• Citric acid (anhydrous): A pH-adjusting agent used to maintain the appropriate acidity of the solution for stability and compatibility with the airways.

Available Pack Sizes

Striverdi Respimat is available in several pack configurations. Not all pack sizes may be marketed in every country:

• 1-pack: 1 Respimat reusable inhaler + 1 cartridge containing 60 puffs (30 doses)
• 3-pack: 1 Respimat reusable inhaler + 3 cartridges, each containing 60 puffs (30 doses)
• 1-pack refill: 1 cartridge containing 60 puffs (30 doses), without inhaler
• 3-pack refill: 3 cartridges, each containing 60 puffs (30 doses), without inhaler

Striverdi Respimat is manufactured by Boehringer Ingelheim Pharma GmbH & Co. KG in Ingelheim am Rhein, Germany, and by Boehringer Ingelheim France in Paris, France. The marketing authorization holder is Boehringer Ingelheim International GmbH. The medication is approved throughout the European Economic Area and in many countries worldwide under the name Striverdi Respimat.